258 related articles for article (PubMed ID: 14726380)
1. Bioengineering of coagulation factor VIII for improved secretion.
Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
[TBL] [Abstract][Full Text] [Related]
2. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
3. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.
Roth SD; Schüttrumpf J; Milanov P; Abriss D; Ungerer C; Quade-Lyssy P; Simpson JC; Pepperkok R; Seifried E; Tonn T
PLoS One; 2012; 7(9):e44505. PubMed ID: 22973456
[TBL] [Abstract][Full Text] [Related]
4. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
5. Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.
Selvaraj SR; Scheller AN; Miao HZ; Kaufman RJ; Pipe SW
J Thromb Haemost; 2012 Jan; 10(1):107-15. PubMed ID: 22044596
[TBL] [Abstract][Full Text] [Related]
6. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII.
Cunningham MA; Pipe SW; Zhang B; Hauri HP; Ginsburg D; Kaufman RJ
J Thromb Haemost; 2003 Nov; 1(11):2360-7. PubMed ID: 14629470
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
[TBL] [Abstract][Full Text] [Related]
8. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
9. Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
[TBL] [Abstract][Full Text] [Related]
10. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin.
Pipe SW; Morris JA; Shah J; Kaufman RJ
J Biol Chem; 1998 Apr; 273(14):8537-44. PubMed ID: 9525969
[TBL] [Abstract][Full Text] [Related]
11. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of native Coagulation factor VIII using the 2A self-processing sequence and furin cleavage site.
He B; Pan Y; Chen L; Xu Y; Chen N; Gu L; Nie Z; Wang S; Liu Z
Thromb Res; 2011 Dec; 128(6):e148-53. PubMed ID: 21803400
[TBL] [Abstract][Full Text] [Related]
14. Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system.
Orlova NA; Kovnir SV; Gabibov AG; Vorobiev II
BMC Biotechnol; 2017 Mar; 17(1):33. PubMed ID: 28340620
[TBL] [Abstract][Full Text] [Related]
15. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
[TBL] [Abstract][Full Text] [Related]
16. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
Andrews JL; Weaver L; Kaleko M; Connelly S
Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
[TBL] [Abstract][Full Text] [Related]
17. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.
Becker S; Simpson JC; Pepperkok R; Heinz S; Herder C; Grez M; Seifried E; Tonn T
Thromb Haemost; 2004 Jul; 92(1):23-35. PubMed ID: 15213841
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
19. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
20. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
